Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 214 of the 217 references it cites were found in a registry or an index; 105 of the 281 sources its claims cite were checked for support.

Fibrosis: from mechanisms to medicines

Open access

Abstract

Fibrosis can affect any organ and is responsible for up to 45% of all deaths in the industrialized world. It has long been thought to be relentlessly progressive and irreversible, but both preclinical models and clinical trials in various organ systems have shown that fibrosis is a highly dynamic process. This has clear implications for therapeutic interventions that are designed to capitalize on this inherent plasticity. However, despite substantial progress in our understanding of the pathobiology of fibrosis, a translational gap remains between the identification of putative antifibrotic targets and conversion of this knowledge into effective treatments in humans. Here we discuss the transformative experimental strategies that are being leveraged to dissect the key cellular and molecular mechanisms that regulate fibrosis, and the translational approaches that are enabling the emergence of precision medicine-based therapies for patients with fibrosis.

Overview

CoChat Summary

TL;DR

This review presents fibrosis as a dynamic, plastic tissue-repair outcome across organs rather than an inevitably irreversible process, and it surveys single-cell and mechanistic discoveries that are reshaping antifibrotic target discovery. It also emphasizes that a translational gap still separates promising preclinical mechanisms from effective precision therapies for patients.

Key findings

  • Fibrosis can affect any organ and is linked to as much as 45% of deaths in industrialized countries; it results from dysregulated repair after chronic or severe injury, with excessive extracellular matrix accumulation disrupting architecture and organ function.
  • Single-cell genomics has uncovered unexpected cellular heterogeneity: over 70,000 multi-lineage cells from 8 human fibrotic lungs and 8 healthy donor lungs revealed a profibrotic alveolar macrophage population; 312,928 cells from 32 IPF, 29 control, and 18 COPD lungs identified IPF-enriched aberrant basaloid epithelial cells; and more than 100,000 human liver cells defined scar-associated TREM2+CD9+ macrophages and ACKR1+/PLVAP+ endothelial subsets.
  • Fibroblasts and macrophages show functional diversity and plasticity, including fascia fibroblasts in skin repair, distinct FAPα+THY1+ versus FAPα+THY1− fibroblast subsets in arthritis, and reprogramming of myofibroblasts toward adipocytes or hepatocyte-like cells.
  • Candidate therapeutic axes include αv integrin-mediated TGF-β activation, IL-17A/TGF-β and type 2 cytokine pathways, metabolic reprogramming such as glycolysis and glutaminolysis, and microbiome/TLR signaling; several agents have entered phase 2 trials, but no metabolism-targeting antifibrotic has reached the clinic.

Methods

  • Narrative review synthesizing mechanistic, preclinical, and clinical literature on fibrosis across multiple organs; no primary experimental data or systematic search strategy is described.
  • Evidence discussed includes mouse injury models such as bleomycin-induced lung fibrosis and carbon tetrachloride-induced liver fibrosis, human tissue single-cell RNA sequencing datasets, primary cell/organoid systems, and clinical trial registry identifiers.
  • The main analysis is a conceptual synthesis organized around single-cell genomics, fibroblast heterogeneity and plasticity, metabolic regulation, macrophage biology, integrin/TGF-β activation, cytokine networks, microbiome contributions, and future therapeutic directions.

Limitations

  • Stated: a translational gap remains between identifying putative antifibrotic targets and producing effective patient therapies; better prognostic animal models and ex vivo human tissue systems are needed, along with validated progression predictors, patient stratification, and more sensitive or clinically meaningful trial endpoints.
  • Stated: safety concerns affect some strategies, including systemic TGF-β inhibition, which risks cardiac valve problems, autoimmunity, and carcinogenesis; a selective anti-αvβ6 IPF trial was terminated because of unspecified safety concerns.
  • Evident: as a narrative review, it lacks a systematic search strategy, quantitative synthesis, and formal risk-of-bias assessment, so its conclusions rest on selected examples and cited studies rather than a comprehensive evidence appraisal.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41586-020-2938-9

Cites

214 of 214 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

23 Valid · 23 Not valid · 112 Not checked · 12 Own results and interpretations

94 more claims · 31 with their cited sources checked

Create a free account to see all 170 claims and to verify the 176 references still open.

See all claims — free account
  • It may state two separate claims as one. 65
  • Probably not a substantial claim. 8

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 217 references

Cited by

See all 1,868

Metadata

Authors
Henderson, N. C., Rieder, F., & Wynn, T. A.
Affiliations
  • Centre for Inflammation Research (GB)
  • Cleveland Clinic (US)
  • Pfizer (United States) (US)
Corresponding author
Wynn, Thomas A.
Venue
Nature
Published
2020-11-25
Volume
587
Issue
7835
Pages
555-566
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W3109793392
Cited by
1,868
References
217
Citations by year
2026: 367 · 2025: 413 · 2024: 407 · 2023: 313 · 2022: 235 · 2021: 131
FWCI
22.62
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
Funders
  • Wellcome Trust (219542/Z/19/Z)
  • Crohn's and Colitis Foundation (569125)
  • British Heart Foundation (RM/17/3/33381, RE/18/5/34216)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK123233, K08DK110415, P30DK097948, T32DK083251)
Topics
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
Keywords
fibrosis, antifibrotic therapy, single-cell profiling, precision medicine, translational research, fibrosis mechanisms
MeSH terms
Gastrointestinal Microbiome, Fibroblasts, Fibrosis, Humans, Macrophages, Mesoderm, Genome, Human, Integrins, Cytokines, Transforming Growth Factor beta, Translational Research, Biomedical, Precision Medicine, Single-Cell Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fibrosis: from mechanisms to medicines. https://app.cochat.ai/papers/10.1038/s41586-020-2938-9
The paper
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020). Fibrosis: from mechanisms to medicines. Nature. https://doi.org/10.1038/s41586-020-2938-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.